Endometrial cancer trial misses, but myelofibrosis sNDA planned for August amid cash crunch
KPTI is trading near its 52-week low of $3.65 (44% below the low) on elevated volume (7.9× avg).
Summary
Karyopharm's endometrial cancer trial failed, but it plans a myelofibrosis sNDA in August. The company is exploring financing and strategic alternatives to address its short cash runway.
Key Events · Product Development and Regulatory · KPTI
-
Endometrial Cancer Trial Miss
The Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer missed its primary endpoint of progression-free survival (HR=0.76, p=0.0791).
-
Myelofibrosis sNDA Planned
An sNDA for accelerated approval of selinexor in myelofibrosis is planned for submission in August 2026, supported by SVR35 data from the SENTRY trial and FDA feedback that the surrogate endpoint is reasonably likely to predict clinical benefit.
-
Financing and Strategic Alternatives Exploration
To extend its cash runway—previously projected only into late Q3 2026—Karyopharm is exploring financing transactions and strategic alternatives with Centerview Partners.
-
Going Concern and Cash Runway Pressure
The company's last 10-Q disclosed a going concern warning and cash runway only into late Q3 2026, making the financing exploration critical for survival.
Analysis · KPTI · Life Sciences
The Phase 3 XPORT-EC-042 trial in endometrial cancer missed its primary endpoint, a setback that follows yesterday's news. However, the company plans to submit an sNDA for myelofibrosis in August 2026, with FDA feedback supporting an accelerated approval pathway. Critically, Karyopharm is now exploring financing and strategic alternatives to extend its cash runway, which was previously projected only into late Q3 2026. With the stock near its 52-week low and a going concern warning already in place, the financing exploration signals urgency and potential dilution or a sale of the company.
At the time of this filing, KPTI was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.9M. The 52-week trading range was $3.65 to $10.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.